ISSN 2321–3647
Sat, 18 Nov 2017

Synthetic Novel 1, 4-Dihydropyridine Derivatives Act as Potential Anticancer Agent Against Both Human Small Cell Lung DMS 114 Cancer Cell Line and Human Colon Cancer Cell Line HCC 2998

Asish Bhaumik1*, Bhargav Bhongiri2, K. Devika1, P. Yadagiri Reddy3, Prasenjit das4

1. Department of Pharmaceutical Chemistry, Teja College of Pharmacy, Kodad, Nalgonda-508206, Telangana State, India.

2. Department of Pharmacology, Vikas College of Pharmaceutical Sciences, Suryapet, Nalgonda-508213, Telangana State, India.

3. Department of Pharmaceutics, Teja College of Pharmacy, Kodad, Nalgonda-508206, Telangana, State, India.

4. Department of Pharmaceutical Chemistry, Regional Institute of Pharmaceutical Science and Technology, Abhoynagar, Agartala-799005, India.


ABSTRACT

The objective of the present work was the synthesis of 1-[5-acetyl-4 (4-substituted phenyl)-2,6-dimethyl-1,4-dihydroxypyridine-3-yl]-ethan-1-one and evaluation of in vitro anticancer activity. Based on this a new series of compound had been planned to synthesize by reacting acetyl acetone with various aromatic aldehydes in the presence of ammonium acetate. The in vitro anticancer activities were carried out against Human small cell lung DMS 114 cell line and Human colon cancer cell line HCC 2998 and MTT assay was used to analyze the cell growth inhibition of the both. The results had been displayed that compound B1-B4 were possessed an excellent anticancer activity (at 25 µg/ml) against both Human small cell lung DMS 114 cancer cell line and Human colon cancer cell line HCC 2998 and doxorubicin (at 10µg/ml) was used as a standard drug for Human small cell lung DMS 114 cancer cell line and 5-Fluro uracil (5-FU) for Human colon cancer cell line HCC 2998. In the present study IC50  values below 4 µg/ml were displayed by the  compound B1 (IC50 of 4.0 µg/ml), B2 (IC50 of 3.4 µg/ml), B3 (IC50 of 3.2 µg/ml) and  B4 (IC50 of 3.1 µg/ml) against Human  small cell lung DMS 114 cancer cell line and  B1( IC50 of 3.5 µg/ml), B2 (IC50 of 3.2 µg/ml), B3 (IC50 of 2.9 µg/ml) and B4 (IC50 of 2.9 µg/ml) against Human colon cancer cell line HCC 2998. The IC50 values of standard drugs doxorubicin and 5-FU were found to be 1. 2 µg/ml and 1.1 µg/ml.

Keywords: IR, NMR, Anticancer activity, DMS 114, HCC 2998, MTT assay, IC50


[PDF]  Viewed: 750  Downloaded: 129
  • Call for paper
    Call for paper

    American Journal of Pharmacy and Health Research (AJPHR) is a peer-reviewed, monthly official international journal allowing access to abstracts and full-text.

  • Email & SMS Alerts
    Email & SMS Alerts

    Email/SMS alert system is one of the key features and gives update information about the submitted manuscript.

    Read more...

  • Article Statastics
    Article Statastics

    American Journal of Pharmacy and Health Research (AJPHR) provides unique facility for authors to know popularity of articles on basis of numbers of PDF download and views. It will display in tabulated format.

  • Online Submission
    Online Submission

    American Journal of Pharmacy and Health Research (AJPHR) is one of the International open access journal devoted to various disciplines in science and technology.

    Read more...

web counter
web counter